98%
921
2 minutes
20
Background And Purpose: Nosocomial infection contributes to the morbidity and mortality of patients in hospital. Timely microbiologic surveillance and assessment of antimicrobial resistance is important for dealing with nosocomial infections. This retrospective review was conducted to evaluate the microbiologic spectrum and susceptibility pattern in the pediatric intensive care unit from 2001 to 2006.
Methods: The microbiologic data and antimicrobial susceptibility of all clinical isolates in the pediatric intensive care unit between 2001 and 2006 were reviewed. The incidence and distribution of nosocomial infections and the associated pathogens were also analyzed.
Results: 1163 clinical isolates were analyzed. The frequencies of Gram-positive and Gram-negative bacteria were 30.4% and 56.2%, respectively. Staphylococcus aureus was the most common isolate among the Gram-positive organisms, while Pseudomonas aeruginosa, Escherichia coli, and Klebsiella pneumoniae were the 3 leading Gram-negative isolates. The proportion of methicillin-resistant S. aureus (MRSA) to all S. aureus was 65.2%. Six vancomycin-resistant enterococci were isolated in 2003. Extended-spectrum beta-lactamase (ESBL)-producing K. pneumoniae accounted for 20% of K. pneumoniae isolates since 2005. Carbapenem-resistant P. aeruginosa accounted for 34% of P. aeruginosa isolates. The nosocomial infection rate was not reduced after moving to a new hospital building in 2003. Urinary tract infection (30.2%) was the most common nosocomial infection, followed by bloodstream infection (26.5%) and lower respiratory tract infection (25.3%).
Conclusions: MRSA, carbapenem-resistant P. aeruginosa, and ESBL-producing K. pneumoniae were the major concerns in this study. Good hand hygiene and strict aseptic procedures remain the most important factors for infection control.
Download full-text PDF |
Source |
---|
Haematologica
September 2025
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD,.
Immunotherapies, including cell therapies, are effective anti-cancer agents. However, cellular product persistence can be limiting with short functional duration of activity contributing to disease relapse. A variety of manufacturing protocols are used to generate therapeutic engineered T-cells; these differ in techniques used for T-cell isolation, activation, genetic modification, and other methodology.
View Article and Find Full Text PDFEmerg Med Australas
October 2025
Australian Centre for Health Services Innovation, School of Public Health & Social Work, Queensland University of Technology, Brisbane, Queensland, Australia.
Reliably defining the risk of adverse in-flight events in aeromedical trauma patients could enable more informed pre-departure treatment and guide central asset allocation to achieve better system-level outcomes. Unfortunately, the current literature base specifically examining the in-flight period is sparse. Flight duration is often considered a proxy for the risk of in-flight deterioration; however, there is limited data to support this commonly held assumption.
View Article and Find Full Text PDFJ Med Chem
September 2025
Guangzhou National Laboratory, Guangzhou 510005, P. R. China.
Respiratory syncytial virus (RSV) is a major pathogen causing acute respiratory infections, and the RSV fusion glycoprotein (F) has been identified as a key target for developing small-molecule inhibitors. Based on our prior identification of lonafarnib as an F protein inhibitor, medicinal chemistry efforts led to the development of , which exhibits significantly enhanced potency against both laboratory and clinical RSV isolates in cellular assays. Time-of-addition and SPR assays indicate that inhibits viral entry by targeting the RSV F protein, but has farnesyltransferase-independent antiviral efficacy.
View Article and Find Full Text PDFACS Biomater Sci Eng
September 2025
Departamento de Genética, Evolução, Microbiologia e Immunologia, Instituto de Biologia, Universidade Estadual de Campinas - UNICAMP, Campinas, São Paulo 13083-862, Brazil.
Violacein exhibits antitumor activity, indicating potential for future clinical application. However, an efficient delivery system is required for the clinical use of this hydrophobic compound. Effective delivery systems can enhance the solubility and bioavailability of hydrophobic compounds like violacein, facilitating its clinical application for antitumor therapy.
View Article and Find Full Text PDFInfect Control Hosp Epidemiol
September 2025
Division of Pediatric Infectious Diseases, Department of Pediatrics, Monroe Carell Jr. Children's Hospital, Vanderbilt University Medical Center, Nashville, TN, USA.
Objective: In the and genes have been associated with elevated MICs to antiseptics with such organisms often termed antiseptic tolerant (ATSA). The impact of repeated healthcare or antiseptic exposure on colonization with ATSA is uncertain.
Design: Prospective longitudinal cohort study.